It's been a huge year for TWLO stock
The Dow is trading higher today, as traders digest earnings and comments from Fed Chair Jerome Powell. Three names making notable moves are cloud concern Twilio Inc (NYSE:TWLO), healthcare specialist Champions Oncology Inc (NASDAQ:CSBR), and drugmaker Cellectar Biosciences Inc (NASDAQ:CLRB). Below, we'll take a closer look at how shares of TWLO, CSBR, and CLRB are trading on the charts.
Bull Note Lifts TWLO Shares to Fresh High
TWLO stock received a price-target hike to $75 from $57 -- in uncharted territory -- at Dougherty, and has gained over 4.6% to trade at $63.96 today. In addition, TWLO earlier hit an annual high of $64.26. It's been a spectacular year for Twilio; thanks to two post-earnings bull gaps it's jumped more than 170% in 2018 -- though it's still staring up at its September 2016 record peak of $70.96. This outperformance has earned the security the confidence of analysts, with 13 of the 14 in coverage handing out "buy" or better ratings.
Meanwhile, put activity has reached extreme levels at the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) -- which is likely due, at least partially, to shareholders protecting paper profits. Specifically, Twillio's 10-day put/call volume ratio across these exchanges stands at 1.24 -- an annual high.
Analyst Expects CSBR Shares to Double
A new "buy" rating and $12 price target from Craig-Hallum has CSBR stock spiking today, last seen up 22.6% at $7.14. The new price target represents expected upside of 106% to Champions Oncology stock's close of $5.82 yesterday.
However, the shares earlier stalled out near the $7.50 level, just below their June two-year highs. Longer term, the equity has mostly been trending higher since touching a multi-year low in August 2016, including a 175% jump in the past 12 months. Craig-Hallum becomes just the third brokerage firm to initiate coverage on the oncology technology provider, with the other two also recommending it as a "buy."
$13 Level Blocks Another CLRB Breakout
CLRB shares are up 13.5% at $8.50, after the company announced upbeat results for a mid-stage trial, with one patient seeing a 94% reduction in tumors after receiving Cellectar Biosciences' CLR 131. Still, the stock earlier hit a speed bump again near the $13 area, which has been a stiff ceiling all year. Nevertheless, the equity is still up roughly 42% since hitting an all-time low below the $6 mark earlier this month.